EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Hemostatic Considerations of New Treatment Options for Hemophilia During Surgery, Infection, and Bleeding in Children and Adolescents

Ivonne Wieland iD, Katharina Becker

Hämostaseologie · 2026-10 · 46 (05) · 317-325

DOI: 10.1055/a-2957-0168 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hämostaseologie, online erschienen am 07.10.2026. Verfasst von Ivonne Wieland und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hannover Medical School, Pediatric Hematology and Oncology, Lower Saxony, Germany, Hannover. Hauptthemen laut MEDLINE: Hemophilia A, Hemostatics, Hemorrhage. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, the therapeutic landscape for hemophilia has changed significantly, with the approval of several innovative agents, some featuring entirely novel mechanisms of action. These advances have substantially improved outcomes and reduced the treatment burden. However, clinical experience with these novel therapies in special situations—such as bleeding, surgery, trauma, and infection—remains limited. Factor replacement therapy has been the standard of care for a long time, with extensive clinical experience. The introduction of non-factor therapies has raised important questions: Is additional treatment required after injury or during surgery? What are the considerations in cases of sepsis or disseminated intravascular coagulation (DIC)? This summary focuses on emicizumab, efanesoctocog alfa, newly approved TFPI inhibitors, nonacog beta pegol, and the extension of indications for PEGylated FVIII preparations to younger age groups. We will therefore also briefly address these developments. The largest part of this manuscript will focus on emicizumab due to its longer approval history and the most extensive data available. Most other medications were licensed in 2024 or later.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHemostaticsHemorrhageHumansAntibodies, Monoclonal, HumanizedChildAdolescentAntibodies, BispecificFactor VIIIPolyethylene GlycolsRecombinant ProteinsFactor Xa

Substanzen

Antibodies, Monoclonal, HumanizedemicizumabAntibodies, BispecificFactor VIIIHemostaticsPRT064445Polyethylene GlycolsRecombinant ProteinsFactor Xa

Autor:innen und Institutionen

  • Hannover Medical School, Pediatric Hematology and Oncology, Lower Saxony, Germany, Hannover.

ORCID-Profile: Ivonne Wieland

Zitieren

APA

Wieland, I., & Becker, K. (2026). Hemostatic Considerations of New Treatment Options for Hemophilia During Surgery, Infection, and Bleeding in Children and Adolescents. Hämostaseologie, 46(05), 317-325. https://doi.org/10.1055/a-2957-0168

Vancouver

Wieland I, Becker K. Hemostatic Considerations of New Treatment Options for Hemophilia During Surgery, Infection, and Bleeding in Children and Adolescents. Hämostaseologie. 2026;46(05):317-325. doi:10.1055/a-2957-0168

BibTeX
@article{Wieland2026,
  author = {Wieland, Ivonne and Becker, Katharina},
  title = {Hemostatic Considerations of New Treatment Options for Hemophilia During Surgery, Infection, and Bleeding in Children and Adolescents},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {05},
  pages = {317--325},
  doi = {10.1055/a-2957-0168}
}
Kostenlos starten →